Abstract
Purpose
Portal vein thrombosis (PVT) is a common condition in cirrhotic patients and mostly attributed to portal hypertension. The objective of our study was to examine the association of PVT with hepatocellular carcinoma (HCC) in cirrhotic patients.
Methods
A retrospective study was performed to identify cirrhotic patients with thrombosis of the portal system. Clinical and laboratory characteristics were collected and analyzed.
Results
Thirty-nine patients were identified. Twenty-four out of 39 patients with PVT did not develop HCC (group A) after follow-up time of 38.5 months from the diagnosis of PVT. Eight patients (20.5%) were diagnosed with HCC within two weeks following diagnosis of PVT (group B). Seven patients (17.9%) were diagnosed with tumor thrombus (group C) at time of PVT diagnosis. The average age was 53.5, 66.5, and 69 years for groups A, B, and C respectively. Most patients (75 and 87.5% for groups B and C respectively) diagnosed with PVT and HCC were males. The most common cause of cirrhosis in groups B and C was chronic hepatitis B virus infection (HBV) in 62.5% and 50% respectively. The most common clinical presentation of PVT in group A was abdominal pain in 55.5% compared to new/worsening ascites in 43% and 37.5% for groups B and C respectively. The platelet count in groups B and C was higher as compared to that in group A (126 and 125 vs. 107 thousand, P = NS).
Conclusion
In 38.4% of cases, new diagnosis of PVT was associated with concomitant diagnosis of HCC. Identifiable risk factors were chronic HBV infection and higher platelet count.
Similar content being viewed by others
Abbreviations
- PVT:
-
Portal vein thrombosis
- HCC:
-
Hepatocellular carcinoma
- MELD:
-
Model for end-stage liver disease
- HBV:
-
Hepatitis B virus
- HCV:
-
Hepatitis C virus
- NASH:
-
Non-alcoholic steatohepatitis
- USD:
-
Doppler ultrasonography
- CT:
-
Computed tomography
- VTE:
-
Venous thromboembolism
- ICD:
-
International Statistical Classification of Diseases and Related Health Problems
- MRI:
-
Magnetic resonance imaging
References
Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.
Tripodi A, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713–23.
Zocco MA, di Stasio E, de Cristofaro R, Novi M, Ainora ME, Ponziani F, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51(4):682–9.
Bechmann LP, Wichert M, Kröger K, Hilgard P. Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int. 2011;31(7):1064.
Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56.
Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik T, van Mourik J. Factor VIII expression in liver disease. Thromb Haemost. 2004;91(2):267–75.
Biagini MR, Tozzi A, Marcucci R, Paniccia R, Fedi S, Milani S, et al. Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. World J Gastroenterol. 2006;12(10):1607–12.
Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol. 1999;94(10):2983–7.
Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol. 2014;11(7):435–46.
Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis. 2010;42(3):163–70.
Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R, Facciorusso D, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol. 2005;17(7):745–51.
Bruix J, Sherman M, D. American Association for the Study of Liver. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
Llado L, et al. Management of portal vein thrombosis in liver transplantation: influence on morbidity and mortality. Clin Transpl. 2007;21(6):716–21.
DeLeve LD, et al. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–64.
Shah V. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. J Clin Gastroenterol. 2007;41(Suppl 3):S259–61.
Lertpipopmetha K, Auewarakul CU. High incidence of hepatitis B infection-associated cirrhosis and hepatocellular carcinoma in the Southeast Asian patients with portal vein thrombosis. BMC Gastroenterol. 2011;11:66.
Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108(4):568–74.
Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. Semin Thromb Hemost. 2010;36(2):170–4.
John BV, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12(6):952–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Khoury, T., Massarwa, M., Hazou, W. et al. Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Canc 50, 759–762 (2019). https://doi.org/10.1007/s12029-018-0149-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-018-0149-5